Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best medical stocks to ...

However, there is also some necessity for visibility, such as the ability to visually confirm the medication inside the vial at the time of use and see the needle tip when extracting the medication ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

(AP Photo/Matt Dunham, File) LONDON (AP) — The lead counsel for a public inquiry into the 2018 death of a British woman poisoned by a Soviet-developed nerve agent said Monday that there was enough ...

In addition, replacing the 500 mg vial with a 250 mg presentation could lower the overall drug waste from 5.8% to 3.2%, creating up to $155 million in annul savings, the team found.

Under the deal terms, Merck will supply KEYTRUDA for the ongoing, Exelixis-sponsored phase 3 STELLAR-305 pivotal trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC.

LONDON — The lead counsel for a public inquiry into the 2018 death of a British woman poisoned by a Soviet-developed nerve agent said Monday that there was enough poison in the vial she ...